SARS-CoV-2 Recombinant Antigen with LRRC24 Penetrating Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine technologies for SARS-CoV-2 lack high-potency solutions to effectively prevent infection by inducing neutralizing antibodies against the virus, particularly in efficiently delivering the antigen to immune cells.
Innovation Solution
A recombinant antigen is developed by fusing the SARS-CoV-2 receptor-binding domain with a cell membrane penetrating domain derived from the human LRRC24 protein, which is encoded by a specific polynucleotide sequence and expressed in eukaryotic cells, allowing for improved immune activation and vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a recombinant antigen using SARS-CoV-2 receptor-binding domain is used, then the antigen can be expressed in eukaryotic cells and discharged out of the cell, but the vaccine potency is insufficient to effectively prevent infection by inducing neutralizing antibodies
Solution Approach 1:
The patent combines the SARS-CoV-2 receptor-binding domain (RBD) with the cell membrane penetrating domain (LRRC24P) derived from human LRRC24 protein to create a fused recombinant antigen. This merging allows the antigen to both bind to viral receptors and actively penetrate into immune cells, thereby enhancing vaccine potency and immune cell activation efficiency simultaneously.
Solution Approach 2:
The cell membrane penetrating domain (LRRC24P) acts as an intermediary that facilitates the delivery of the RBD antigen into immune cells. This mediator enables the antigen to cross the cell membrane barrier, improving the efficiency of immune cell activation and enhancing overall vaccine effectiveness.
2Ease of manufacture
If the receptor-binding domain is expressed without a cell membrane penetrating domain, then the expression and discharge of antigen is simple, but the ability to activate immune cells is insufficient
Solution Approach 1:
The patent merges the RBD antigen with the LRRC24P cell membrane penetrating domain in a single fusion protein construct. This combination maintains the simplicity of eukaryotic cell expression and discharge while adding the critical function of immune cell penetration and activation, thereby resolving the contradiction between manufacturing simplicity and immune activation capability.
Data Source
AI summary
Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.